Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 3 of 17 for:    cytosorb

CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery (REFRESH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by CytoSorbents, Inc
Information provided by (Responsible Party):
CytoSorbents, Inc Identifier:
First received: September 28, 2015
Last updated: April 22, 2016
Last verified: April 2016
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.

Condition Intervention
Elective Cardiac Surgery
Device: CytoSorb

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

Resource links provided by NLM:

Further study details as provided by CytoSorbents, Inc:

Primary Outcome Measures:
  • Change in plasma free hemoglobin [ Time Frame: From Start of cardiopulmonary bypass procedure and end of cardiopulmonary bypass procedure (e.g. approximately 3 hours) ]
  • Assessment of serious device related adverse events [ Time Frame: From time of enrollment through ICU discharge (e.g. ICU stay of approximately 4 days) ]

Secondary Outcome Measures:
  • Ventilator time [ Time Frame: From start of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days) ]
  • Time in the ICU [ Time Frame: From the end of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days) ]
  • Days in the hospital [ Time Frame: From the end of the cardiopulmonary bypass procedure through hopsital discharge (e.g. ICU stay of approximately 4 days) ]
  • Incidence/progression of Acute Kidney Injury [ Time Frame: From Baseline through ICU discharge (e.g. ICU stay of approximately 4 days) ]
  • mortality [ Time Frame: From time of enrollment through 30 days post procedure ]
  • Adverse event rates [ Time Frame: through 30 days ]
  • Vital signs [ Time Frame: From Baseline through ICU discharge (e.g. ICU stay of approximately 4 days) ]
  • Safety Laboratory assessments [ Time Frame: From Baseline through ICU discharge (e.g. ICU stay of approximately 4 days) ]

Estimated Enrollment: 56
Study Start Date: November 2015
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CytoSorb Device
Standard of care plus treatment with CytSorb device installed on the CPB machine
Device: CytoSorb
Cytosorb device use during cardiopulmonary bypass
No Intervention: Control
Standard of care


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of >180 minutes

Exclusion Criteria:

  • Platelet count < 20,000/ uL
  • Body mass index <18
  • Pregnant women
  • Life expectancy of <14 days
  • End stage organ disease
  • Active infection
  • Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure
  • Contraindication to anticoagulation with heparin
  • Declined informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02566525

Contact: Steve Sisk, MSc Pharmacy 732 329 8885 ext *40
Contact: Sarah Grzyb 5083518632 ext 208

United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States
United States, Massachusetts
Baystate Medical Recruiting
Springfield, Massachusetts, United States
United States, New Jersey
Cooper University Hospital Recruiting
Camden, New Jersey, United States
United States, New York
Columbia University Recruiting
New York, New York, United States
United States, Pennsylvania
University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States
Sponsors and Collaborators
CytoSorbents, Inc
Study Director: Steve Sisk, MSc Pharm CytSorbents
  More Information

Responsible Party: CytoSorbents, Inc Identifier: NCT02566525     History of Changes
Other Study ID Numbers: 2015-001
Study First Received: September 28, 2015
Last Updated: April 22, 2016

Keywords provided by CytoSorbents, Inc:
CytoSorb device
Plasma free hemoglobin
extracorporeal bypass processed this record on April 28, 2017